The serotonin selective reuptake inhibitors (SSRIs) have clinically and aneedotally been associated with nausea and weight loss as a side etTect of their action. The tricyclic antidepressants have been linked to carbohydrate (CHO) craving and weight gain in patients with major depressive disorders. This side effect has been attributed to the strong anti-histaminergic actions of these agents and is recognized as a causal factor of non-compliance in a substantial percentage of patients.
INTRODUCTION
Fluoxetine, fluvoxamine , paroxetin e, sertraline and citalopram. collectively referred to as selective serotonin reuptake inhibitors (SSRls), have introduced significant advances to the long-term and acute management of depression (Kasper and Heiden, 1995) , primarily due to a highly selective action and distinct pharmacokinetic advantages. Tricyclic antidepressants (TCt\s) have a non-selective action on biogenjc amine and other receptors (Beaumont et al. , 1995) , resulting in non-specific binding to a range of receptors, viz. muscarinic (mAG:H), histam ine (H)-1 and , ",, -ad renergic receptors leading to the typical TCAassociated side effects. These actions underlie the high incidence of cognitive dysfunction, dry mouth, constipation and visual disturbances due to their strong antimuscarinic actions, cardiovascular instability due to their "'-adrenolytic actions, while weight gain and sedation are proposed to be due their antihistaminergic effects (Beaumont et al., 1995) .
Targeted drug design has allowed the SSRls to widen the concentration gradient between select actions on serotonin (5-HT) uptake and interactions © 1996 Rapid Science Publishers at the above receptors (Hyttel, 1994) . However, in te ractions at some receptor sites still occur and, due to structural differences, they appear to vary in intensity from one SSRI to the next. Consequently, sertraline and paroxetine display higher binding affinities for mACH receptors while citalopram is characterized by a greater degree of binding to H-l receptors compared to other SSRls (Hyttel, 1994; Leonard, 1995) .
The question arises whether these affinities are clinically relevant. Certainly, paroxetine displays an affinity for mACH receptors similar to imipramine (Richelson, 1994) and has been associated with the highest incidence of antimuscarinic side effects compared to the other SSRls (Finley, 1994) . A higher incidence of sedation, in agreement with a potential ant ihista minergic action on arousal mechanisms (Richelson, 1994) , appears to occur with citalopram (Finley, 1994) . Furthermore, despite an improved side effects profile, the selective action on 5-HT uptake by SSRls has revealed that these drugs can prese nt with not o nly non-specific 5-HT-mediated side effects such as nausea, headaches, agitation, etc.
International Clinical Psychopharmacology . Val1l . 1996 273 , , . . , (Beaumont et ai., 1995) , but also some rare but serious adverse effects such as parkinsonism, dystonia and the serotonin syndrome, which appear to be due to excessive 5-HT-mediated suppression of dopamine (DA) activi ty in the striatum (Sternbach, 1991; Arya, 1994) . In this paper, we review the case material of eight patients seen in our clinic, where we descibe for the first time the induction of CHO craving, with associated weight gain, in patients treated for affeclive disorders with citalopram, a highly potent and selective SSRI (Hyttel, 1994) . Possible mechanisms are discussed.
CASE STUDIES
Eight patients who presented to our outpatient anxiety disorder and mood disorder clinics are described herein. None of the patients displayed features of atypical depression, i.e. reverse diurnal rhythm, CHO craving and hypersomnia prior to treatment. Two cases are described and the data of the remainder are C. D . BOUWER AND B. H. HARVEY summarized in Table l . Table II presents a week-byweek weight analys is for each patient.
Case 1
A 28-year-old married female presented with a history of depressed mood associated with co-morbid panic attacks. She was initially treated with fluoxetine 20 mglday but developed agitation and refused further treatment with this agent because of adverse press publicity surrounding its use. She was subsequently treated with citalopram 20 mglday. After 10 days she reported an increase in finding and seeking behaviour for CHO-rich foods. This was documented to commence at approximately 15.00 h every day. On entry to the treatment programme she was 1.74 m tall and weighed 54 kg. Over 4 weeks of treatment, her body weight increased steadily to reac h 62 kg at week 4 (Table II) . The Montgomery Asbe rg Depression Rating Scale (MADRS) dropped from 28 to 20, Hamilton Depression Rating Scale (HAM-D) from 26 to 17 and the Hamilton Anxiety Rating Scale (HAM-A) from 32 to 19 (Table I) . There was an improvement in Clinical Global Impressio n (CGI) from 5 to 2 (Table I) . Because of her increase in weight, citalopram was stopped on the patient's request and at a 2-week follow-up she had lost 2.4 kg. She was not on a kilojoule-rest ricted diet or exercise programme.
Case 2 A 1.9-m-tall, 42-year-old married man with panic disorder was referred to the anxiety disorders clinic. Previous pharmacologi cal treatment had included imipramine 150 mg/day, buspirone 10 mg twice daily and clomipramine 150 mg/day. The latter agent was discontinued because of weight gain. He was treated with citalopram 20 mg/day. Baseline weight was 64 kg. After 6 days he complained of CHO craving from 14.00 h, a dry mouth and drowsiness. His body weight increased steadily from 64 kg at the start of week 1 to 69 kg at week 4 (Table II) . The MADRS changed from 11 to 9, HAM-D from 14 to 11 and the HAM-A from 34 to 15 (Table I ). The CGI improvement changed from 6 to 2 (Table I) . Despite his dissatisfaction with the weight increase, he elected to continue with the treatment programme. At the end of week 5 his weight was 73 kg, at which point he initiated his own exercise programme. His weight stabilized.
Although citalopram effectively addressed the depressive symptoms, the patient's craving for CHO persisted and at 7-month follow-up he had not attained his pre-treatmen t weight. In total, 18 patients in our clinic had received citalopram as monotherapy, with eight of these presenting with symptoms of CHO craving and weight gain. In all cases described, citalopram was administered at the same time each morning. There were no pre-morbid features to suggest the presence of atypical depression or an impulse control disorder. None of the subjects had a history of an eating disorder. An obvious change in weight was noticeable within 7-10 days (Table II) . These patients described an intense craving for CHO starting early in the afternoon and persisting until the late evening with a subsequent increase in weight. Except for the patient described in case 2, all the patients requested discontinuatio n of their medication after 4 weeks. As in case 1, said discontinuation of citalopram resulted in a gradual return to pre-treatmen t body weight (data not shown). Despite this effect on weight, 4 weeks' exposure to citalopram resulted in a favourable clinical response in both the depressed mood and panic attack frequency, intensity and quality as demonstrated by the CGI and change in HAM-D, HAM-A and MADRS rating scales. Response to citalopram was relatively rapid with a reduction in clinical symptoms.
DISCUSSIO N
In this report we present evidence that treatment of mood disorders with the SSRI citalopram may be associated with CHO craving and weight gain in susceptible patients.
Neurochemic al studies provide evidence that a host of neurotransmi tters and peptides, operating alone or in concert, are involved in the complex central and peripheral regulation of appetite behaviour. These include noradrenaline (NA), DA and 5-HT as well as neuropeptides such as cholecystokin in, corticotrophin releasing factor, neuropeptide Y and opioids (Blundell, 1990; Goldbloom ef al., 1991; Lambert ef aI. , 1993) . When considering the biogenic amines specifically, the involvement of 5-HT is well recognized (Leibowitz, 1990; Goldbloom ef aI., 1991). DA involvement is suggested in that phenothiazine s and butyrophenon es are known to induce weight gain, an effect linked to an increased appetite and rate of eating with DA receptor blockade (Blundell, 1990; Goldbloom ef al., 1991) . Alpha-2 noradrenergi c receptors in the paraventricul ar nucleus (PVN) of the medial hypothalamus operate in concert with 5-HT to modulate CHO ingestion (Leibowitz, 1990; Goldbloom ef al., 1991) . Similarly, hypothalamic histamine exerts an inhibitory action on feeding via histaminergic projections to the ventromedial and PVN (Sakata ef al., 1990), such that inhibition of histamine results in an inability to detect a low protein diet with resultant weight gain (Mercer et al., 1994) .
Reports of persistent weight gain with SSRIs have not been documented. The observations presented in these case studies may reflect two scenarios, i.e. a structurally specific action of citaiopram, or a yet unrecognized rare event possible with other SSRls as well. The biochemical basis for these observations is of great interest but is, at best, speculative, especially since 5-HT has been found to control the ratio of CHO versus protein intake, with 5-HT stimulation being essential in reducing the proportion of CHO in the diet (Leibowitz, 1990) . This would predict that the SSRIs, including citalopram, will exert either a reduction, or at best a limited effect, on CHO craving and weight gain. Our observations appear paradoxical, given the potent and selective 5-HT-enhanci ng action of citalopram (Hyttel, 1994) . However, a neurochemical basis for this paradox may involve DA and/or histamine, with 5-HT playing an integral role in the ultimate response.
Although the affinity of citalopram for DA receptors and DA uptake mechanisms are unremarkable (Hytell, 1994) , a possible explanation for our results may involve DA. DA blockade is associated with an increase in caloric intake (Gold bloom el ai., 1991). The SSRIs, via 5-HT-mediated suppression of DA pathways in the striatum, are rarely associated with symptoms indicative of DA hypofunction, e.g. extrapyramidal effects and dystonia (Arya, 1994) . The effect of DA on feeding has been related to "hedonic" eating as part of a reward system (Goldbloom e/ ai., 1991). Anatomically, there is evidence to support s~ch an interaction and 5-HT and DA terminals have been found to converge in the ventrolateral nucleus accumbens (Phe1ix and Broderick, 1995), the latter nuclei forming part of the DA reward system (Hyman and Nestler, 1996) . In support of this, in vivo microdialysis studies in rats indicate that f1uoxetine, a less potent SSRI, can engender significant suppression of DA accumulation in the nucleus accumbens (Ichikawa and Meltzer, 1995) . However, f1uoxetine is best known for its anorectic action in humans (Wise 1992; Finley, 1994) . Furthermore, studies in obese patients have revealed significant weight-reducing efficacy with high-dose f1uoxe tine (60 mg/day; Wise, 1992; Golelstein el ai., 1994), while a recent citalopram stuely (60 mg/day) failed to reach a similar conclusion (Szkudlarek and Elsborg, 1993) . Obvious differences in 5-HT uptake affinity and 5-HT/NA se lectivity be tween SSRls have not proved to be clinically relevant (Leonard, 1995) and it is speculative that these differences may predict differential actions on DA function. However, other pharmacological differences in histamine and 5-HT receptor binding are evident. The enantiomers (Wong et al., 1991) . Fluoxetine also appears to act as a 5-HT releaser (Leibowitz, 1990) . Among the SSRIs, citalopram presents with the highest affinity for the HI receptor (Ki=470 nM; Richelson and Nelson, 1984; Hytell, 1994) . This affinity figure, while still significantly low by TCA standards (e.g. dothiepin K j -3.6 nM, amitryptiline K j =l.1 nM; Richelson and Nelson, 1984) , inte rprets an affinity for the HI receptor roughly 13 times more potent than f1uoxetine (K j =6200; Richelson and Nelson, 1984 (Sakata et ai., 1990; Mercer el al., 1994; Tuomisto, 1994) , such a cause and effect relationship appears more compkx in humans. Still, this mechanism has been cited as the reason for the weight increase seen with certain TCAs (Richelson, 1994; Beaumont el aI., 1995) . However, pure HI antagonists, with the exception of phenothiazine derivatives, are not associated with weight gain (McEvoy, 1991) . Cyproheptadine is the exception, having an ability to increase CHO intake in both rats and humans with an associated increase in weight (Leibowitz, 1990; Sanders-Bush and Mayer, 1996) . Howeve r, cyproheptadine is not only an HI antagonist, but also blocks 5-HT, receptors (Sanders-Bush and Mayer, 1996) . Citalopram and trazodone (K j =350 nM) display similar dissociation constants for the HI receptor (Richelson and Nelson, 1984) . The latter has been associated with weight gain in clinical studies (Marek el ai., 1992; Weisler et ai., 1994) . However, as with cyproheptadine, the effects of trazodone on weight may involve both an HI and 5-HT, antagonistic profile (Marek el ai., 1992). This combined action seems necessary since pooled analysis of placebo-controlled trials of nefazodone, a chemically and pharmacologically related agent with similar 5-HT, blocking action but insignificant H I blockade (Preskorn, 1995) , revealed no changes in weight between nefazodone and placebo (Physicians Desk Reference, 1995) . Although citalopram does not block 5-HT, receptors (Hyttel, 1994) , acute administration of citalopram (or any SSRI) may be expected to induce an initial suppression of 5-HT release, and a reduction in 5-HT, receptor stimulation, due to a compensatory presynaptic action by 5-HT'A auto receptors to reduce the sudden increase in 5-HT activity (Goodwin, 1996) . This together with an acute Hl block, may engender a response analogous to that seen with cyproheptadine. This acute effect is expected to wane over a few weeks due to desensitization of 5-HT 13 receptors resulting in increased stimulation of 5-HTI receptors. We were not able to confirm this since all but case 2 opted to discontinue ciraiopram after 4 weeks . An interesting observation of the present study was that all the subjects experienced a phasic craving for sweetness, suggesting that circadian feeding patterns, where ingestion of CHO-rich food is usually under strict 5-HT control in the medial hypothalamus (Leibowitz, 1990) , may be suppressed through disruption of ventromedial HN5-HT function by citalopram.
In conclusion, this paper emphasizes a potential risk of weight gain, related to an in creased craving for CHO, in patients receiving citalopram. These observations were noted during acute treatment (within 4 weeks). The underlying mechanisms need to be investigated further, and whether these acute effects do in fact, disappear over long-term use. This may h~ve significant clinical relevance, esp ecially in depressed patIents, as well as those suffering from eating disorders such as bulimia nervosa, where an obsession with weight may lead to non-complian ce. In addition, there are distinct compliance consideration s in depressed patients who are already obese, or those who have pre-establishe d problems with weight manage ment. However, this same property may be desirable in the treatment of co-morbid depression in patients suffering from anorexia nervosa wh e re an anorectic action may be counter·produ ctive, or when marked weight loss is associated with depression.
Clearly, controlled comparative clinical trials n eed to be undertaken to access these assumptions in the above populations.
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